Drugs

, Volume 61, Issue 6, pp 789–796 | Cite as

Desloratadine

Adis New Drug Profile

Abstract

  • ▴ Desloratadine is the orally active major metabolite of the nonsedating H1-antihistamine loratadine.

  • ▴ The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers. Therapeutic dosages had no effects on wakefulness or psychomotor performance in healthy volunteers.

  • ▴ No clinically significant interactions have been reported between desloratadine and drugs that inhibit the cytochrome P450 system, nor does the drug potentiate the adverse psychomotor effects of alcohol.

  • ▴ Oral desloratadine 5mg once daily for up to 4 weeks in patients with seasonal allergic rhinitis (SAR) significantly reduced nasal (including congestion) and non-nasal symptoms and improved health-related quality of life compared with placebo. Similar beneficial effects were observed in patients with SAR and coexisting asthma (in whom asthma symptoms and use of β2-agonists were reduced).

  • ▴ Desloratadine 5mg once daily for 6 weeks significantly improved pruritus and reduced the number of hives compared with placebo in patients with chronic idiopathic urticaria (CIU). Sleep and daytime performance also improved.

  • ▴ Desloratadine was well tolerated in clinical trials and had an adverse event profile similar to that of placebo in patients with SAR (with or without asthma) or CIU.

Keywords

Terfenadine Loratadine Fexofenadine Seasonal Allergic Rhinitis Desloratadine 

References

  1. 1.
    Handley DA, Magnetti A, Higgins AJ. Therapeutic advantages of third generation antihistamines. Expert Opin Invest Drug 1998; 7(7): 1045–54CrossRefGoogle Scholar
  2. 2.
    Simons FER. H1-receptor antagonists: comparative tolerability and safety. Drug Saf 1994; 10(5): 350–80PubMedCrossRefGoogle Scholar
  3. 3.
    Salata JJ, Jurkiewicz NK, Wallace AA, et al. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995; 76(1): 110–9PubMedCrossRefGoogle Scholar
  4. 4.
    Du Buske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 1999 Feb; 21: 281–95CrossRefGoogle Scholar
  5. 5.
    Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000 Apr; 50: 345–52Google Scholar
  6. 6.
    Vignola AM, Crampette L, Mondain M, et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995 Mar; 50: 200–3PubMedCrossRefGoogle Scholar
  7. 7.
    Bayram H, Devalia JL, Khair OA, et al. Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured bronchial epithelial cells. J Allergy Clin Immunol 1999; 104: 93–9PubMedCrossRefGoogle Scholar
  8. 8.
    Genovese A, Patella V, De Crescenzo G, et al. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc ‘epsilon’ RI+ cells. Clin Exp Allergy 1997; 27: 559–67PubMedCrossRefGoogle Scholar
  9. 9.
    Kleine-Tebbe J, Josties C, Frank G, et al. Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine. J Allergy Clin Immunol 1994; 93: 494–500PubMedCrossRefGoogle Scholar
  10. 10.
    Lippert U, Kruger-Krasagakes S, Moller A, et al. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995 Aug; 4 (4 Pt 2): 272–6PubMedCrossRefGoogle Scholar
  11. 11.
    Horak F, Stiibner P, Zieglmayer R, et al. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis [abstract no. 1000]. Allergy 2000; 55 Suppl. 63: 279Google Scholar
  12. 12.
    Kreutner W, Hey JA, Chiu P, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000 May; 50: 441–8Google Scholar
  13. 13.
    Banfield C, Padhi D, Glue P, et al. Electrocardiographic effects of multiple high doses of desloratadine [abstract]. J Allergy Clin Immunol 2000 Jan; 105 (1 Pt 2): 383CrossRefGoogle Scholar
  14. 14.
    Marino M, Glue P, Herron JM, et al. Lack of electrocardiographic effects of multiple high doses of desloratadine [abstract no. 999]. Allergy 2000; 55 Suppl. 63: 279Google Scholar
  15. 15.
    Scharf MB, Kay G, Rikken G, et al. Dosloratadine has no effect on wakefulness or psychomotor performance [abstract no. 1001]. Allergy 2000; 55 Suppl. 63: 280Google Scholar
  16. 16.
    Vuurman E, Ramaekers JG, Rikken G, et al. Desloratadine does not impair actual driving performance: a 3-way crossover comparison with diphenhydramine and placebo [abstract no. 945]. Allergy 2000; 55 Suppl. 63: 263–4Google Scholar
  17. 17.
    Herron JM, Padhi D, Affrime MB, et al. Dose-proportionality, linearity, and pharmacokinetics of desloratadine in healthy adults [abstract]. J Allergy Clin Immunol 2000 Jan; 105 (1 Pt 2): S385CrossRefGoogle Scholar
  18. 18.
    Gupta S, Padhi D, Banfield C, et al. The effect of food on the oral bioavailability of desloratadine [abstract]. J Allergy Clin Immunol 2000 Jan; 105 (1 Pt 2): 386–7CrossRefGoogle Scholar
  19. 19.
    Padhi D, Banfield C, Gupta S, et al. Multiple-dose pharmacokinetics, safety, and tolerance of desloratadine in healthy volunteers [abstract]. J Allergy Clin Immunol 2000 Jan; 105 (1 Pt 2): 385CrossRefGoogle Scholar
  20. 20.
    Rosenberg MA, Cohen A, Padhi D, et al. Multiple-dose pharmacokinetics of desloratadine in subjects differing in race and gender [abstract]. J Allergy Clin Immunol 2000 Jan; 105 (1 Pt 2): 386CrossRefGoogle Scholar
  21. 21.
    Affrime MB, Banfield C, Glue P, et al. Desloratadine and ketoconazole: pharmacokinetics and electrocardiographic pharmacodynamic effects [abstract]. J Allergy Clin Immunol 2000 Jan; 105(1 Pt 2): 386CrossRefGoogle Scholar
  22. 22.
    Brannan M, Affrime M, Cayen M. Effects of various cytochrome P450 inhibitors on the clearance of loratadine (L)/descarboethoxyloratadine (DCL) and lack of effects of increased L and DCL plasma concentrations on QTc intervals [abstract]. Allergy 1997; 52 Suppl. 37: 207Google Scholar
  23. 23.
    Glue P, Banfield C, Affrime MB, et al. Desloratadine and erythromycin: pharmacokinetics and electrocardiographic pharmacodynamic effects [abstract]. J Allergy Clin Immunol 2000 Jan; 105 (1 Pt 2): 387CrossRefGoogle Scholar
  24. 24.
    Banfield C, Gupta S, Kantesaria B, et al. No drug interaction between fluoxetine and desloratadine, a new nonsedating once-daily antihistamine [abstract no. 529]. J Allergy Clin Immunol 2001 Feb; 107 (2 Pt 2)Google Scholar
  25. 25.
    Cayen M, Wang E, Clement RP, et al. Effect of desloratadine on p-glycoprotein transport system (MDR1) [abstract]. Allergy 2000; 55 Suppl. 63: 282Google Scholar
  26. 26.
    Gupta S, Banfield C, Lim J, et al. Unlike fexofenadine, the pharmacokinetics of desloratadine are minimally altered by coadministration with azithromycin [abstract no. 524]. J Allergy Clin Immunol 2001 Feb; 107 (2 Pt 2)Google Scholar
  27. 27.
    Banfield C, Gupta S, Cayen M, et al. Grapefruit juice has no effect on the biovailability of desloratadine, but reduces the cmaxand AUC of fexofenadine by 30% [abstract]. Am Coll Allergy, Asthma Immunol; 2000 Nov 3–8; SeattleGoogle Scholar
  28. 28.
    Rikken G, Scharf MB, Danzig MR, et al. Desloratadine and alcohol coadministration: no increase in impairment of performance over that induced by alcohol alone [abstract no. 993]. Allergy 2000; 55 Suppl. 63: 277Google Scholar
  29. 29.
    Meltzer EO, Prenner BM, Nayak A, et al. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 2001; 21(1): 25–32CrossRefGoogle Scholar
  30. 30.
    Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001; 40: 1–5CrossRefGoogle Scholar
  31. 31.
    Finn A, the Desloratadine Study Group. Desloratadine has an early onset of action and long-term benefit for S AR symptoms [abstract]. Am Coll Allergy, Asthma Immunol; 2000 Nov 3–8; SeattleGoogle Scholar
  32. 32.
    Nayak A, Lorber R, Salmun LM. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis [abstract]. J Allergy Clin Immunol 2000 Jan; 105 (1 Pt 2): 384CrossRefGoogle Scholar
  33. 33.
    Nathan R, the Desloratadine Study Group. Desloratadine relieved nasal congestion in patients with seasonal allergic rhinitis and concurrent asthma [abstract and slide presentation]. American College of Allergy, Asthma and Immunology; 2000 Nov 3–8; SeattleGoogle Scholar
  34. 34.
    Corren J, Salmun LM. Quality of life in patients with seasonal allergic rhinitis is improved by desloratadine [abstract no. 676]. Allergy 2000; 55 Suppl. 63: 191Google Scholar
  35. 35.
    Schmier J, Leidy N, Heithoff K, et al. Health-related quality of life outcomes of desloratadine in patients with moderate-to-severe SAR [abstract]. Am Coll Allergy, Asthma and Immunol; 2000 Nov 3–8; SeattleGoogle Scholar
  36. 36.
    Corren J, The Desloratadine Study Group. Desloratadine reduces the use of inhaled beta2-agonists and improves asthma symptoms in patients with seasonal allergic rhinitis and asthma [abstract no. 134]. J Allergy Clin Immunol 2001 Feb; 107(2 Pt 2)Google Scholar
  37. 37.
    Ratner PH, The Desloratadine Study Group. Long-term benefit of desloratadine against seasonal allergic rhinitis symptoms in patients with asthma [abstract no. 531]. J Allergy Clin Immunol 2001 Feb; 107 (2 Pt 2)Google Scholar
  38. 38.
    Berger WE, The Desloratadine Study Group. Desloratadine reduces seasonal allergic rhinitis symptoms in patients with seasonal allergic rhinitis and asthma [abstract no. 533]. J Allergy Clin Immunol 2001 Feb; 107 (2 Pt 2)Google Scholar
  39. 39.
    Schenkel E, the Desloratadine Study Group. Desloratadine improved SAR symptoms in patients with mild to moderate asthma and SAR [abstract]. Am Coll Allergy, Asthma Immunol; 2000 Nov 3–8; SeattleGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations